Primary Menu

Skip to content

PCR
Apoptosis Assays
Suppliers
Contact us

Menu

Biocat Net

Amine biocat 3.0

PCR

PCR primers

Search for:

Recent Posts

The pharyngeal nervous system orchestrates feeding behavior in planarians.
A comprehensive annotation and differential expression analysis of short and long non-coding RNAs in 16 bat genomes.
Dual Oxidase-Derived Reactive Oxygen Species Against Bacillus thuringiensis and Its Suppression by Eicosanoid Biosynthesis Inhibitors.
Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma.
Double-Stranded RNA Technology to Control Insect Pests: Current Status and Challenges.

FierceBiotechFollow

Tweets by the Fierce Life Sciences editorial team. Subscribe to our daily email newsletter at http://t.co/32BWEhDPPD

FierceBiotech @FierceBiotech·

9 Jul

Finerenone beat placebo at staving off kidney failure—when patients need dialysis or a transplant to survive—death from kidney disease or slowing decline in estimated glomerular filtration rate, namely the rate at which the kidneys could filter blood. https://www.fiercebiotech.com/biotech/bayer-s-heart-failure-pill-hinders-kidney-disease-heart-disease-phase-3

Reply on Twitter 1281231252436275201 Retweet on Twitter 1281231252436275201 Like on Twitter 12812312524362752015 Twitter 1281231252436275201

FierceBiotech @FierceBiotech·

9 Jul

Forbion has followed fellow European VCs Medicxi and Sofinnova Partners in expanding beyond early-stage investing. https://www.fiercebiotech.com/biotech/forbion-moves-into-late-stage-investing-210m-fund

Reply on Twitter 1281193898388455425 Retweet on Twitter 12811938983884554251 Like on Twitter 12811938983884554253 Twitter 1281193898388455425

FierceBiotech @FierceBiotech·

9 Jul

The startup comes to life with $30 million to discover and develop new medicines for neurodegenerative and aging-related diseases that target neuroinflammation through a key metabolic pathway. https://www.fiercebiotech.com/biotech/tranquis-debuts-30m-for-immune-cell-approach-to-neurodegenerative-disease

Reply on Twitter 1281186006662873096 Retweet on Twitter 12811860066628730964 Like on Twitter 12811860066628730966 Twitter 1281186006662873096

FierceBiotech @FierceBiotech·

9 Jul

“Sanofi is transforming our R&D organization to focus on the development of first-in-class or best-in-class medicines. Our collaboration with Kymera is integral to the overall strategy." https://www.fiercebiotech.com/biotech/sanofi-pays-150m-upfront-2b-biobucks-to-tap-protein-degrader-biotech-kymera

Reply on Twitter 1281185842007085056 Retweet on Twitter 12811858420070850566 Like on Twitter 128118584200708505631 Twitter 1281185842007085056

FierceBiotech @FierceBiotech·

9 Jul

Tofersen is designed for patients with a genetic form of ALS, stemming from a mutation in the SOD1 gene. https://www.fiercebiotech.com/biotech/biogen-s-antisense-als-drug-checks-boxes-phase-1-2-en-route-to-phase-3-readout

Reply on Twitter 1281170274214436867 Retweet on Twitter 12811702742144368674 Like on Twitter 12811702742144368676 Twitter 1281170274214436867

FierceBiotech @FierceBiotech·

8 Jul

Biogen will arrive at the FDA with results from one trial that suggest aducanumab is no better than placebo and data from another that link it to improved scores on a dementia scale. https://www.fiercebiotech.com/biotech/a-test-for-hahn-s-fda-biogen-submits-controversial-alzheimer-s-drug-aducanumab

Reply on Twitter 1280878401012760578 Retweet on Twitter 1280878401012760578 Like on Twitter 12808784010127605785 Twitter 1280878401012760578

FierceBiotech @FierceBiotech·

8 Jul

Precision, which is predominately working on next-gen cancer therapies, will regain the license to its hep B program. https://www.fiercebiotech.com/biotech/gilead-axes-445m-precision-biosciences-gene-therapy-hep-b-pact

Reply on Twitter 1280846452818939911 Retweet on Twitter 1280846452818939911 Like on Twitter 1280846452818939911 Twitter 1280846452818939911

Jomsom by Catch Themes

Scroll Up

PCR
Apoptosis Assays
Suppliers
Contact us